Dao-Pei Lu May 2010, Shanghai Hematopoietic Stem Cell Transplantation (HSCT) in China (2010)

Slides:



Advertisements
Similar presentations
台北榮總血液腫瘤科 楊元豪 / 高志平大夫. 2 Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative treatment in patients.
Advertisements

Congenital Neutropenia: Making the Decision to Transplant John E. Levine, MD, MS University of Michigan Blood and Marrow Transplantation Program.
G. S / AIH 2006 Aplastic anemia; treatment options Gérard Socié, MD PhD Hospital Saint Louis.
Regenerative Medicine to Cure Sickle Cell Anemia Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Director: Division of Adult.
A single centre study of the efficacy of extracorporeal photopheresis in Acute Graft Versus Host Disease Lynne Watson Nottingham University Hospital NHS.
Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies Xiao-Jun Huang M.D. Ph.D. Peking University Institute of Hematology,
Hematopoietic stem cell transplantation
Peking University People’s Hospital & Institute of Hematology Beijing Key Laboratory of HSCT, Beijing, P.R.China Xiao-Jun Huang M.D Donor Lymphocyte Infusion.
UNRELATED DONOR TRANSPLANTS A Bacigalupo, Ospedale San Martino, Genova, Italy.
Transplantation of hematopoietic stem cells in pediatric oncology Vladivostok State Medical University Foreign languages department Vladivostok 2012 Scientific.
NK cell therapy after transplantation Miltenyi Satellite Symposium
CHIMERISM & DLI Dr. Serdar ŞIVGIN Kayseri Feb, 2011.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.
Allogeneic Stem Cell Transplantation: The Journey
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.
Advances in SCT in Acute Leukemia 충남대학교병원 혈액종양내과 조 덕 연.
DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN.
1 Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée Marseille, France ALLOGENEIC STEM CELL TRANSPLANTATION.
林建廷 April 28,  IPSS for MDS (FAB classification) ◦ Greenberg P et al. International scoring system for evaluating prognosis in myelodysplastic.
DONOR LYMPHOCYTE INFUS I ON (DLI) Dr. Serdar ŞIVGIN February 2011 Kayseri.
Current Status of Acute Myeloid Leukemia in China Jianxiang Wang Institute of Hematology Hospital of Blood Disease Chinese Academy of Medical Sciences.
Allogeneic “Mini” Transplantation Mark B. Juckett M.D. June 4, 2004.
Optimizing Timing of Transplant in Hodgkin Lymphoma Ginna G. Laport, MD Associate Professor of Medicine Division of Blood & Marrow Transplantation Stanford.
HAPLOIDENTICAL STEM CELL TRANSPLANT
Hematopoietic Stem Cell Current Status and Future Directions
Abstract Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic.
Hematopoietic Stem Cell Transplantation (HSCT)
Margaret L. Green, Wendy M. Leisenring, Hu Xie, Roland B. Walter, Marco Mielcarek, Brenda M. Sandmaier, Stanley R. Riddell and Michael Boeckh Blood NUM.
Pavan Kumar Bhamidipati 1, John F. DiPersio 1, Keith Stockerl-Goldstein 1, Geoffrey L. Uy 1, Peter Westervelt 1, Feng Gao 2, Ravi Vij 1, Mark A. Schroeder.
Time to neutrophil engraftment Time to platelet engraftment
Retrospective analysis of conditioning regimen containing decitabine of allogeneic stem cell transplantation for myelodysplastic syndrome and myeloproliterative.
Case Western Reserve University and University Hospitals of Cleveland
EBMT Activity Survey Teams Patients Transplants
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al
Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Different Characteristics between Acute Myelogenous.
at First Pavlov State Medical University of Saint-Petersburg, Russia
The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-
Allogeneic stem cell transplantation (allo-SCT) is a potentially curative procedure for a variety of malignant and nonmalignant conditions. Historically,
EBMT Activity Survey Teams 39,313 Patients 43,636 Transplants
EBMT Activity Survey Teams Patients Transplants
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
Whom should you refer for allogeneic stem cell transplantation?
Intravenous Busulfan-Cyclophosphamide as a Preparative Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Acute.
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA
Haploidentical BMT with Post Transplant Cyclophosphamide
Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children with Malignant and Nonmalignant Diseases: End of the Beginning and Future.
Letermovir(Prevymis™) Guidelines for Inpatient Use
Qualitative and quantitative PCR monitoring of minimal residual disease (MRD) in relapsed poor-risk chronic lymphocytic leukemia (CLL): early assessment.
Hematopoietic Stem Cell Transplantation for Patients with AML
Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia  Mei-Jie.
Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation,
Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.
Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation.
Biology of Blood and Marrow Transplantation
Sequential Intensified Conditioning and Tapering of Prophylactic Immunosuppressants for Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell.
The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review 
Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring.
Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid.
Is KIR- typing relevant to HCT donor selection?
Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.
Hematopoietic Stem Cell Transplantation Dr . Ghassemi A Associate professor of pediatric Hematologist Oncologist & stem cell transplantation.
Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-
Clinical Lymphoma, Myeloma and Leukemia
Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse 
Bridge to transplant following Bv+Bs regimen.
Timing for HCT Consultation
by Jan J. Cornelissen, and Didier Blaise
Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease 
Presentation transcript:

Dao-Pei Lu May 2010, Shanghai Hematopoietic Stem Cell Transplantation (HSCT) in China (2010)

1 CSBMT and Syn-HSCT

Establishment of CSBMT (Chinese Society of BMT) Hangzhou, establishment of Chinese BMT Cooperation Group in APBMT and China BMT Group meeting Beijing, establishment of CSBMT in ISH-APD & APBMT meeting Hong-Kong, Chinese BMT Forum

1 st CSBMT Conference (2009, Hong Kong)

CSBMT Newsletter

Syn-HSCT in Chinese --A report of 94 cases from 32 centers in CSBMT

Patient characteristics CSBMT AA AML large granular lymphocytosis Neuroblastoma lymphoma MDS CML ALL n=94

OS of Syn-HSCT (n=94)

DFS of Syn-HSCT (n=94)

Follow-up the longest survivor of HSCT in the world

2 Overview of HSCT in China

HSCT Number in Different Cities in China

HSCT Number in Different Units in China

HSCT indications in China ( 2009 ) MM Other leukemia Autoimmune disease Solid tumor AA

Types of HSCT in China ( 2009 ) Identical sibling Haplo Unrelated Auto Syngeneic

GIAC Principle Combined BM & PB C:C: ATG A:A: Immuno-suppression intensified and prolonged I : G-CSF mobilization GG:GG:

Haploidentical HSCT (Haplo-HSCT) Lu et al. Blood 2006; 107: 3065

Haploidentical Blood and Marrow Transplantation in Hematological Malignancies: A Single- Center Report of 290 patients Tong Wu, Dao-Pei Lu, et al. Beijing Daopei Hospital, Beijing, China August th APBMT

Outstanding Oral Presentation Award (Haplo-HSCT) 14th APBMT (August 2009, Korea)

II-IV aGVHD III-IV aGVHD Days after BMT Percent 34.9% 16.0% Acute GVHD of Haplo-HSCT (Beijing Daopei Hospital, n=290)

standard risk high risk advanced Years after BMT LFS 73.9% 51.0% 22.2% P< LFS of Haplo-HSCT (Beijing Daopei Hospital, n=290)

standard risk high risk advanced Years after BMT OS 77.3% 58.1% 29.5% P< OS of Haplo-HSCT (Beijing Daopei Hospital, n=290)

Indications of Unrelated-HSCT (U-HSCT) ( Beijing Daopei Hospital, n=182)

Acute GVHD of U-HSCT (Beijing Daopei Hospital, n=182)

5yr-OS of U-HSCT (Beijing Daopei Hospital, n=182) 72.2%

5yr-DFS of U-HSCT (Beijing Daopei Hospital, n=182) 64.9%

U-HSCT with Haplo-BM (Beijing Daopei Hospital, n=182)

Successful Rescue of Refractory/Recurrent Myelogenous Leukemia by Allogeneic HSCT and Prophylactic Immunotherapy Beijing & Shanghai Daopei Hospitals

Refractory/recurrent myelogenous leukemia by HSCT and immunotherapy 30 cases (AML 29 , CML-BC myeloid 1) Median blasts in BM 36 ( )% Types of HSCT: –Matched sibling5 –Unrelated7 –Haploidentical18 Median follow-up 17 (5 - 37) months

Conditioning <40% blasts in BM –Ara-C + BuCy13 >40% blasts in BM –Chemotherapy + reduced BuCy 6 Impaired organs : –Fludarabine substituted for Cy11

Prophylaxis of Relapse –Immunosuppressants were tapered off early post-HSCT –Prophylactic immunotherapy if no GVHD Cellular: DLI, DC-CIK, NK cells Humoral: IL-2, IFN-a, thymosin

Refractory/recurrent myelogenous leukemia by HSCT and immunotherapy OS EFS

3 Further application of HSCT

A Special Neonatal Case of SCID cured by U-CBT Dao-pei Hospital & Pediatric Hospital, Fu Dan University

Reconstitution PLT WBC N# L#

U-CBT 前

U-CBT 后 5 个月

Familial Hemophagocytic Lymphohistiocytosis (FHL) treated by U-HSCT Beijing Daopei Hospital

Patient Zhang x. 13 yr girl “Lymphoma” was diagnosed and treated in other hospitals. FHL was diagnosed on admission.

Zhang’s Family Tree Diagnosed as FHL-2

MACPF 结构域 野生型 PRF1-168SMACPF 结构域 突变型 PRF1-168N MHD2 结构域 野生型 UNC13D-863GMHD2 结构域 突变型 UNC13D-863D Protein conformation of PRF1 gene mutations Paternal Maternal

Perforin normalization post HSCT of Zhang Y Month

Autologous cord blood transplantation (Auto- CBT) in children Beijing Children’s Hospital (BCH) Beijing Daopei Hospital (BDH)

Auto-CBT in Children Date of HSCT HospitalDiagnosisFollow- up (month) Outcome BCHNeuroblas toma 2CR BDHSAA4CR BDHSAA3CR

Auto-CBT for pediatric SAA Beijing Daopei Hospital Before HSCT

Summary 1 、 CSBMT must play an important role in HSCT continuously. 2 、 Large series of syn-HSCT show excellent outcome in both nonmalignant and malignant hematological diseases.

Summary 3 、 HSCT in China has been developing rapidly. The outcomes of Haplo-HSCT and U-HSCT have achieved top level in the world in experienced units. 4 、 DFS in refractory/recurrent myeloid leukemia treated by allo-HSCT and immunotherapy has been improved significantly.

Summary 5 、 More and more diseases could be treated by HSCT, such as allo- HSCT for inherited diseases (SCID, FHL) and auto-CBT for solid tumor and SAA.

Acknowledgment